A new group led by the Biotechnology Innovation Organization (BIO) is urging Congress to create additional incentives for drug and biologic makers to develop innovative antibiotics, starting with passage of the Medicare add-on payments included in the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. The group, Working to Fight AMR, includes representatives from Merck, Novo Holdings, Paratek Pharmaceuticals and Boston University School of Law. Greg Frank, the director of the group and director of infectious...